Promising personalized therapeutic options for diffuse large B-cell lymphoma subtypes with oncogene addictions
Clinical Cancer Research, 07/03/2012
Steinhardt J et al. – The study integrated genomic analysis and functional screens to provide a rationale for targeted therapies within defined populations. Personalizing treatments by identifying patients with oncogenic dependencies via genotyping and specifically targeting the responsible drivers may constitute a novel approach for the treatment of diffuse large B–cell lymphoma (DLBCL).